Predictive Oncology Inc. POAI Archives

WednesdayAug 18, 2021 3:20 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Approval of Charter Amendment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate of incorporation. The amendment, effective Aug. 17, 2021, increased the number of authorized shares of company common stock from 100,000,000 to 200,000,000. According to the update, the approval was granted at the special meeting of stockholders convened on Aug. 10, 2021, and adjourned to Aug. 17, 2021. To view the full press release, visit https://ibn.fm/f6pqT About Predictive Oncology Inc. Predictive Oncology operates through three segments…

TuesdayAug 17, 2021 9:30 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies

AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library Model learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in the space where artificial intelligence and precision medicine intersect, Predictive Oncology (NASDAQ: POAI) has released initial results for its AI-driven models of ovarian cancer (https://ibn.fm/H3As3). According to Predictive Oncology, the initial results demonstrate that AI models of genomic data can predict cancer outcomes which has…

WednesdayAug 11, 2021 11:54 am

QualityStocksNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The reason for the adjournment was to solicit more votes on a key proposal. According to the announcement, the proposal in questions calls for approval of an amendment to the company’s certificate of incorporation to increase the number of authorized shares of company common stock to…

TuesdayJul 27, 2021 3:43 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he…

FridayJul 16, 2021 1:48 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment. “While others must wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine,” a recent article reads. “Predictive Oncology presently has the clinical information, including tumor drug response data and…

FridayJul 09, 2021 11:08 am

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers,” reads a recent article. “‘In previous conferences, Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their…

WednesdayJul 07, 2021 10:25 am

Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries

Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits TumorGenesis will use its GMP lab to produce its proprietary media that tricks tumor cells into growing outside the body the same as inside the body in addition to producing proteins and other biological products used in diagnosing, treating, and modifying tumor cells On the heels of raising $21.34 million and three…

FridayJul 02, 2021 10:53 am

Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine

Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space Predictive Oncology is strong standout in precision medicine Predictive Oncology (NASDAQ: POAI) has closed on its registered direct offering (https://ibn.fm/9buhx).The offering, which totaled $21.34 million, will be a boon for the knowledge-driven company as it continues its focus on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. Operating in the AI space, the company is looking at almost vast potential as…

FridayJul 02, 2021 10:38 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth…

ThursdayJun 24, 2021 2:14 pm

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI